Kisspeptin Peptide Therapy in Alpharetta

What kisspeptin is

Kisspeptin is a naturally occurring neuropeptide hormone that sits at the top of the reproductive hormone cascade, acting on the hypothalamic-pituitary-gonadal (HPG) axis. It is produced by the KISS1 gene and signals through the receptor GPR54 to trigger release of gonadotropin-releasing hormone, which in turn drives luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release (Ratnasabapathy & Dhillo, Current Drug Targets, 2013). Unlike several compounds on this site, kisspeptin has a real and expanding human clinical research program behind it, much of it conducted by a research group at Imperial College London.

This is the compound on our peptide pages with the clearest, best-designed human trial evidence, and we want to be equally clear about what that evidence covers. It comes from controlled academic studies using research-grade infusion protocols in specific patient populations, under close monitoring, not from a commercially available product with an established safety and dosing profile for general use.

How it is thought to work

Kisspeptin's core, best-established mechanism is neuroendocrine: it stimulates GnRH neurons, which drives downstream release of LH and FSH, the hormones that regulate ovulation, spermatogenesis and sex-steroid production (Jayasena et al., Journal of Clinical Endocrinology and Metabolism, 2011). Separately, researchers have studied whether kisspeptin also modulates brain regions involved in sexual and emotional processing, proposing a second, less established pathway connecting reproductive hormone signaling to sexual response and mood-related brain activity.

What the research shows

The reproductive-hormone research is the most established strand. A controlled human study found that intravenous kisspeptin-10 increased serum LH and FSH in healthy men and in women during the preovulatory phase of the menstrual cycle, but did not alter gonadotropin levels in women during the follicular phase, demonstrating that responses differ by sex and by menstrual-cycle timing (Jayasena et al., 2011). A related review describes kisspeptin's role in the HPG axis and its exploration as a potential approach to conditions such as hypothalamic amenorrhoea and infertility, while noting this remains a research and therapeutic-implications discussion rather than an approved application (Ratnasabapathy & Dhillo, 2013).

The sexual-response strand is newer and comes primarily from Imperial College London. In a randomized, placebo-controlled crossover trial in men with hypoactive sexual desire disorder, intravenous kisspeptin-54 modulated brain activity during sexual-video viewing, increased penile tumescence relative to placebo, and improved behavioral measures of sexual desire and arousal (Mills et al., JAMA Network Open, 2023). This is a genuine, peer-reviewed, controlled human trial, and it is also a single trial in a specific population — men diagnosed with hypoactive sexual desire disorder — using a research infusion protocol, not a general finding that kisspeptin enhances sexual function in the broader population. Separately, kisspeptin-54 has also been studied as a trigger for oocyte maturation in women undergoing IVF, a distinct clinical research application with its own evidence base.

Across both strands, the research is legitimate and growing, and it remains investigational. These are controlled academic trials, not the basis for an approved treatment, and effect sizes, durability and safety over repeated or longer-term use are still being established.

What it is not

Kisspeptin is not FDA approved for hormone signaling disorders, infertility, or low sexual desire. It is not a verified libido treatment for general use outside a study population, and the sexual-response findings described above come from a specific clinical trial in men with a diagnosed condition, not from population-wide evidence. It is not interchangeable with established hormone therapies for infertility or hypogonadism, and it is not something a member can simply request; the research to date has taken place under controlled trial protocols with monitoring in place. It has not been studied for general use in women with low libido to the same degree as in men, so extending the men's HSDD findings to women, or to anyone without a diagnosed desire disorder, is not something the evidence currently supports.

How Aeon approaches it

We do not sell, prescribe or supply kisspeptin. Where hormone signaling, libido or fertility concerns bring a member in, the appropriate first step is a full hormonal picture through clinic-lab-services and evaluation by a licensed provider through our hormone therapy pathway, which can identify what is actually driving symptoms before any conversation about an investigational compound takes place. Kisspeptin's research trajectory is one we watch closely, and we would rather describe it accurately today than overpromise ahead of the evidence.